StockHealthcare · BIOTECHNOLOGY

$SABSW

SAB Biotherapeutics, Inc.

Price · $SABSWvia TradingView

AI sentiment · 7d0 articles

No enriched coverage for $SABSW in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $SABSW in the last 30 days.

SAB BIO Highlights Data in Multiple Presentations at EASD - SAB Biotherapeutics ( NASDAQ:SABSW ) , SAB Biotherapeutics ( NASDAQ:SABS )

-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study-

SEP 3·Benzinga

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes - SAB Biotherapeutics ( NASDAQ:SABSW ) , SAB Biotherapeutics ( NASDAQ:SABS )

MIAMI, Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- SAB Biotherapeutics, Inc.

via TradingView

News on $SABSW

All news →